Joseph Haas

Latest From Joseph Haas
Sarepta’s Exondys 51 Successor On Clinical Hold, But Quick Resolution Expected
The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.
Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Are Market Conditions Setting Up A Biopharma M&A Wave?
A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.
Athira Says Phase II Alzheimer’s Miss Will Inform Ongoing Phase III Study
Athira hoped a small Phase II study would show a benefit on working memory processing speed, but it missed its primary and all secondary endpoints, reducing confidence in the Phase III program.
Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance
Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.
Third Rock Thinks Its Model Reassures Investors In Difficult Times
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.